Evidence map›Paper›PMID 15681406›Full record

ArticleJournal of virology2005

Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Donald N Forthal, Gary Landucci, Tran B Phan, Juan Becerra

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Functions of Antibodies.Microbiology spectrum · 2014
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. New paradigms for HIV/AIDS vaccine development.Annual review of medicine · 2012
    Review
  12. Article
  13. Article
  14. Review
  15. The humoral response to HIV-1: new insights, renewed focus.The Journal of infectious diseases · 2010
    Review
  16. Article
  17. Is developing an HIV-1 vaccine possible?Current opinion in HIV and AIDS · 2010
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Donald N ForthalDepartment of Medicine, Division of Infectious Diseases, University of California, Irvine, School of Medicine, Route 81, 101 City Dr., Orange, CA 92868, USA. dnfortha@uci.edu
Gary Landucci
Tran B Phan
Juan Becerra
University of California, Irvine · US

Funding

Novel Biological Activities of Anti-Viral AntibodyR01AI052039 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2002 to 2006
$1.5M
NIAID NIH HHS R01 AI052039
6 · The paper itself

Abstract

Antibodies can prevent lentivirus infections in animals and may play a role in controlling viral burden in established infection. In preventing and particularly in controlling infection, antibodies likely function in the presence of large quantities of virus. In this study, we explored the mechanisms by which antibodies neutralize large inocula of human immunodeficiency virus type 1 (HIV-1) on different target cells. Immunoglobulin G (IgG) from HIV-infected patients was tested for neutralizing activity against primary R5 strains of HIV-1 at inocula ranging from 100 to 20,000 50% tissue culture infective doses. At all virus inocula, inhibition by antibody was enhanced when target cells for virus growth were monocyte-depleted, peripheral blood mononuclear cells (PBMCs) rather than CD4(+) lymphocytes. However, enhanced inhibition on PBMCs was greatest with larger amounts of virus. Depleting PBMCs of natural killer (NK) cells, which express Fc receptors for IgG (FcgammaRs), abrogated the enhanced antibody inhibition, whereas adding NK cells to CD4(+) lymphocytes restored inhibition. There was no enhanced inhibition on PBMCs when F(ab')(2) was used. Further experiments demonstrated that the release of beta-chemokines, most likely through FcgammaR triggering of NK cells, contributed modestly to the antiviral activity of antibody on PBMCs and that antibody-coated virus adsorbed to uninfected cells provided a target for NK cell-mediated inhibition of HIV-1. These results indicate that Fc-FcgammaR interactions enhance the ability of antibody to neutralize HIV-1. Since FcgammaR-bearing cells are always present in vivo, FcgammaR-mediated antibody function may play a role in the ability of antibody to control lentivirus infection.

Indexed as

Acquired Immunodeficiency SyndromeCD4-Positive T-LymphocytesHIV-1HIV AntibodiesHumansImmunoglobulin Fc FragmentsKiller Cells, NaturalLeukocytes, MononuclearNeutralization TestsHIV AntibodiesImmunoglobulin Fc Fragments

Identifiers

PMID15681406
PMCPMC546539
OpenAlexW2134934974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.